Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Director | July 31, 2026 | August 04, 2026 |
| GT Biopharma, Inc.GTBP · Entity 7878 | Director | September 04, 2025 | September 08, 2025 |
| GridAI Technologies Corp.FWBI · Entity 7534 | Director | January 02, 2024 | January 04, 2024 |
| International Stem Cell CORPISCO.OB · Entity 8432 | Director | June 21, 2018 | June 25, 2018 |
| PaxMedica, Inc.PXMD · Entity 93047 | Director | March 12, 2024 | March 14, 2024 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Director | December 12, 2025 | December 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 10,000 · Balance 10,000 F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
GT Biopharma, Inc.
Report date September 04, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2035-08-19 | Direct | 62,500 |
Reported balance
After 2025-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-04 · Grant · Acquired 62,500 · Balance 62,500 F1: The options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The options are fully vested and exercisable.
GridAI Technologies Corp.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,937 |
Reported balance
After 2024-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 19,633 · Balance 19,937 F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 2, 2024, the Reporting Person was granted 19,633 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024.
F2: Includes unvested RSUs.
International Stem Cell CORP
Report date June 21, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,431 |
Reported balance
After 2018-06-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-21 · Grant · Acquired 4,328 · Balance 14,431 F1: Common stock granted as part of compensation for non-employee directors, with vesting at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock granted as part of compensation for non-employee directors, with vesting at the time of grant.
PaxMedica, Inc.
Report date March 12, 2024 · Filed March 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,386 |
Reported balance
After 2024-03-12 transaction · row 1
1 source rowRow 1 · 2024-03-12 · Tax withholding · Disposed 992 · Balance 2,386 F1: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by issuer to satisfy tax withholding obligations of reporting person resulting from vesting of restricted stock units.
RELMADA THERAPEUTICS, INC.
Report date December 12, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $4.06 · Expires 2035-12-12 | Direct | 164,000 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Grant · Acquired 164,000 · Balance 164,000 F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2018 Filed Nov 16, 2018 00:24 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 5,000 | $6.00 | $30,000.00 |
DisclosureSEC source: 0001209191-18-058827 · doc4.xml · nonDerivative · entry 2 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,420 Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 00:24 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | ConversionCommon Stock | 8,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-058827 · doc4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock. The shares have no expiration date. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 00:05 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 7,500 | $2.57 | $19,275.00 |
DisclosureSEC source: 0001415889-18-001448 · form4-10012018_051003.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2018. Read SEC document |
| June 29, 2018 Filed Jul 16, 2018 23:22 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-001119 · form4-07162018_040747.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending June 30, 2018. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:18 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 4,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-18-001777 · ownership.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,431 F1 · security: Common stock granted as part of compensation for non-employee directors, with vesting at the time of grant. Read SEC document |
| May 16, 2018 Filed May 16, 2018 22:55 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GiftCommon Stock | 12,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-18-001445 · casamento_frm4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,103 F1 · price: The reported transaction involves a transfer of securities by gift for which no payment of consideration was received by the reporting person. Read SEC document |
| March 30, 2018 Filed Apr 4, 2018 17:31 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 5,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-18-000920 · casamento_frm4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,383 F1 · security: Common Stock granted as part of compensation for non-employee directors, with vesting at the time of grant: Q1 2018. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:16 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 7,500 | $3.14 | $23,550.00 |
DisclosureSEC source: 0001415889-18-000490 · form4-04022018_010405.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · kind: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending March 31, 2018. Read SEC document |
| January 09, 2018 Filed Feb 1, 2018 20:12 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GiftCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-18-000266 · casamento_f4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,856 F1 · price: The reported transaction involves a transfer of securities by gift for which no payment of consideration was received by the reporting person. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 22:17 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 5,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-18-000016 · casamento_f4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,856 F1 · security: Common Stock granted as part of compensation for non-employee directors, with vesting at the time of grant: Q4 2017. Read SEC document |
| December 20, 2017 Filed Feb 13, 2018 22:31 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-000227 · form5-02132018_020254.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending December 31, 2017. Read SEC document |
| October 20, 2017 Filed Oct 23, 2017 20:36 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 425,000 | $0.81 Strike: $0.81 | $344,250.00 |
DisclosureSEC source: 0001213900-17-010831 · f4101917casamento_relmada.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2027-10-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 21:44 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-17-001685 · form4-10232017_021008.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · price: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarters ending March 31, 2017, June 30, 2017, and September 30, 2017. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 23:48 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 4,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-17-002549 · casamento_f4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,681 F1 · security: Common Stock granted as part of compensation for non-employee directors, with vesting at the time of grant: Q3 2017. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 21:48 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 7,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-17-001722 · casamento_frm4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,266 F1 · security: Common Stock granted as part of compensation for non-employee directors, with vesting at the time of grant: Q2 2017. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 17:19 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001683168-17-001477 · casamento_f4.xml · derivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest fully on the earlier of (i) May 31, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, with vesting accelerated for all shares in the event of a change in control. All grants have an exercise price of $1.10 per share. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 17:14 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 4,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-17-000764 · casamento_f4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,139 F1 · security: Common Stock granted as part of compensation for non-employee directors, with vesting at the time of grant. Q1 2017. Read SEC document |
| December 30, 2016 Filed Dec 30, 2016 19:55 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 7,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-16-001038 · casamento_f4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,497 F1 · security: Common Stock granted as part of compensation for non-employee directors, with vesting at the time of grant. Q4 2016. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 19:39 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-16-000322 · casamento_f4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,974 F1 · security: Common Stock granted as part of compensation for non-employee directors (Annual Grant), with vesting at the time of grant. Read SEC document |
| September 30, 2016 Filed Sep 30, 2016 20:52 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantCommon Stock | 4,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-16-000226 · casamento_frm4.xml · nonDerivative · entry 1 CASAMENTO CHARLES J · CIK 0001117167 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,640 F1 · security: Common Stock granted as part of compensation for non-employee directors, with vesting at the time of grant. Q3 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.